Andere talen Iterum Therapeutics plc

Aandelen

ITRM

IE000TTOOBX0

Vertraagde tijd Nasdaq Andere beurzen 15:32:32 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,51 ^USD	-1,30%		-2,57%	-23,35%

29/04	Iterum Therapeutics dient opnieuw een New Drug Application in bij de U.S. Food and Drug Administration voor orale sulopenem	CI
28/03	Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29/04
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29/04
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	28/03
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/03
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	21/03
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat	15/03
Iterum Therapeutics Provides Business Update	06/03
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives	06/03
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint	30/01
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	30/01
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	30/01
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023	29/12
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule	04/12
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Iterum Therapeutics Reports Third Quarter 2023 Financial Results	14/11
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023	07/11
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24-10-23
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24-10-23
Iterum Therapeutics to Present Data at IDWeek 2023	12-10-23
Iterum Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	02-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Iterum Therapeutics plc

Aandelen

ITRM

IE000TTOOBX0

Andere talen

Filters